Deliberate AI, a digital health company specialising in AI-driven mental health assessment, has achieved a significant milestone as the U.S. Food and Drug Administration (FDA) selected its AI-generated Clinical Outcome Assessment (AI-COA) for inclusion in the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program. The collaboration between Deliberate AI and the FDA is seen as a major advancement in mental health research, leveraging AI to accelerate drug development, enhance treatment effectiveness, and provide more empowering outcomes for patients.
Deliberate AI's AI-COA utilises cutting-edge multimodal signal processing and machine learning to quantitatively capture mental health symptoms. This innovative approach offers advantages over traditional methods, including objectivity and consistency by removing human bias, enhanced precision through the analysis of subtle behavioural cues, and real-time insights by continuously monitoring patients throughout clinical trials. The FDA's recognition of AI-COA in the ISTAND program marks a pivotal moment in mental health research, as it is the first time the agency has embraced an AI/ML and Digital Health Technology initiative for the program. This acknowledgement underscores the FDA's commitment to fostering innovation in drug development and evaluation, particularly in the realm of mental health where traditional methods face limitations.
Marc Aafjes, Founder & CEO of Deliberate AI, highlighted the FDA's recognition as a new era in developing and monitoring treatments for depression and anxiety. The inclusion of AI-COA in the ISTAND program is expected to pave the way for more efficient and faster clinical trials, addressing critical barriers in psychiatric drug development and ultimately leading to improved patient care and a significant impact on public health.
Click here to read the original news story.